Lv617
2350 积分 2024-07-16 加入
The reporting odds ratio and its advantages over the proportional reporting ratio
24天前
已完结
Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: a pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database
1个月前
已完结
Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: a pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database
1个月前
已完结
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system
2个月前
已完结
A real-world drug safety surveillance study of lenvatinib from the FAERS database
2个月前
已完结
Therapeutic efficacy of CD34+ cell-involved mononuclear cell therapy for no-option critical limb ischemia: A meta-analysis of randomized controlled clinical trials
3个月前
已完结
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab
3个月前
已关闭
USF1‐induced overexpression of long noncoding RNA WDFY3‐AS2 promotes lung adenocarcinoma progression via targeting miR‐491‐5p/ZNF703 axis
4个月前
已关闭
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab
5个月前
已完结
A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database
5个月前
已完结
皖公网安备34019202002308
